Muscle Disease Section

The Muscle Disease Section focuses its research on myositis, a rare family of autoimmune diseases in which the body's immune system attacks healthy muscle tissue, causing inflammation, weakness, fatigue, and pain in skeletal muscles. Problems that affect the skin, lungs, and joints often accompany myositis.

Research Focus:

  • Dermatomyositis, which can include a skin rash.
  • The anti-synthetase syndrome, which can include a rash, lung disease, and arthritis.
  • Inclusion body myositis, which typically affects the muscles of older adults.
  • Immune-mediated necrotizing myopathy, which can cause especially severe weakness in children and adults alike.

Lab Goals:

  • Define the different subtypes of autoimmune muscle disease based on muscle histology, autoantibodies, and other biomarkers.
  • Describe the role of myositis autoantibodies in the pathogenesis of myositis.
  • Develop animal models of myositis that are relevant to human diseases.
  • Understand how environmental exposures, including medications such as statins and cancer immunotherapies, can trigger autoimmune muscle disease.
  • Use novel therapeutic strategies to treat myositis patients at the NIH Clinical Center.

In 2007, while on the faculty at Johns Hopkins, Dr. Mammen co-founded the Johns Hopkins Myositis Center. This group discovered a form of immune-mediated necrotizing myopathy triggered by statins, a medication used to lower cholesterol concentrations ( Arthritis Rheum 63:713–721, 2011 ). This disease occurs in approximately 1 in 50,000 Black and white Americans exposed to statins. However, working with colleagues in New Mexico, they found that around 1 in 300 members of the Navajo Nation may develop this form of myositis if exposed to statins ( Arthritis Rheum 2022; DOI:10.1002/art.42126 ). Dr. Mammen's research continues to investigate why some people can safely use statins while others have an increased risk of developing myositis and should avoid this cholesterol-lowering medication.

Related NIAMS Labs

Scientific Advances block_2 a:6:{s:6:"header";N;s:6:"offset";N;s:8:"argument";N;s:5:"pager";N;s:5:"limit";N;s:5:"title";i:0;}

Postdoctoral Fellows

  • Sandra Muñoz-Braceras, Ph.D., 2019-2024
  • Jose Milisenda, M.D., Ph.D., 2021-2022
  • Jiram Torres Ruiz, M.D., 2021-2022
  • Angela Quintana Vega, Ph.D., 2020-2021
  • Hilal Cevik, M.D., 2019 (2 months)
  • Albert Gil Vila, M.D., 2019 (3 months)
  • Andres Baucells de la Pena (Visiting Fellow) 2018
  • Benjamin Plotz, M.D., 2018 (1 month)
  • Sara Sabbagh, D.O., 2017-2019

Pre-doctoral Fellows

  • Bianca Campbell, 2022 (two months)
  • Rose Graf, 2018-2019
  • Rebecca De Lorenzo, 2017
  • Richard Yeker, 2016-2018
  • David Amici, 2016-2017
  • Cassie Parks, 2015-2017
  • Wilson Huang , 2014-2016

Postbac Fellows

  • Jon Musai, 2022-2024

Clinical Fellows

  • Amara Ogbonnaya, 2024-2025
  • Matthew Sherman, 2021-2023

Muscle Disease Unit Clinical Research Immunology Muscle Biology

Image
A montage of research images arranged in circular frames.
block_5 a:6:{s:6:"header";N;s:6:"offset";N;s:8:"argument";s:7:"145+149";s:5:"pager";N;s:5:"limit";N;s:5:"title";i:0;}

Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis.

Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, Pak K, Miller FW, Milisenda JC, Grau-Junyent JM, Selva-O'Callaghan A, Carrion-Ribas C, Paik JJ, Albayda J, Christopher-Stine L, Lloyd TE, Corse AM, Mammen AL

Ann Rheum Dis.

2020 Sep;

79(9).

doi: 10.1136/annrheumdis-2019-216599

PMID: 32546599

Identification of distinctive interferon gene signatures in different types of myositis.

Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, Pak K, Plotz P, Miller FW, Milisenda JC, Grau-Junyent JM, Selva-O'Callaghan A, Paik J, Albayda J, Christopher-Stine L, Lloyd TE, Corse AM, Mammen AL

Neurology.

2019 Sep 17;

93(12).

doi: 10.1212/WNL.0000000000008128

PMID: 31434690

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1.

Mammen AL, Rajan A, Pak K, Lehky T, Casciola-Rosen L, Donahue RN, Lepone LM, Zekeridou A, Pittock SJ, Hassan R, Schlom J, Gulley JL

Ann Rheum Dis.

2019 Jan;

78(1).

doi: 10.1136/annrheumdis-2018-213777

PMID: 30185415

Statin-Associated Autoimmune Myopathy.

Mammen AL

N Engl J Med.

2016 Feb 18;

374(7).

doi: 10.1056/NEJMra1515161

PMID: 26886523

Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy.

Mammen AL, Tiniakou E

N Engl J Med.

2015 Oct 22;

373(17).

doi: 10.1056/NEJMc1506163

PMID: 26488714

Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy.

Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, Casciola-Rosen LA

Arthritis Rheum.

2011 Mar;

63(3).

doi: 10.1002/art.30156

PMID: 21360500

block_1 a:6:{s:6:"header";N;s:6:"offset";N;s:8:"argument";s:3:"412";s:5:"pager";N;s:5:"limit";N;s:5:"title";i:0;}

Image
Photograph showing faces of the six lab members standing in a line.
See all Publications on PubMed